Circulating tumor necrosis factor-α concentrations in a native canadian population with high rates of type 2 diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 1, 1999, Pages 272-278

  Zinman, Bernard ^a,c   Hanley, Anthony J G ^a   Harris, Stewart B ^b   Kwan, Jeremy ^a   Fantus, I George ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LEPTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; CANADA; CORRELATION FUNCTION; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; BLOOD PRESSURE; CANADA; CHILD; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; REGRESSION ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032922944     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.1.272     Document Type: Article

References (56)

1. 1. Zimmett P, Dowse G, Bennett P. Hyperinsulinaemia is a predictor of non-insulin dependent diabetes mellitus. Diabetes Metab. 17:101-108.
2. 2. Rewers M, Hamman RF. 1995 Risk factors for non-insulin dependent diabetes mellitus. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America, 2nd ed. National Diabetes Data Group. Bethesda: U.S. Government Printing Office; NIH Publication 95-1468; pp 179-220.
3. 3. Reaven GM. 1988 Role of insulin resistance in human disease. Diabetes. 37:1595-1607.
4. 4. DeFronzo RA, Ferrannini E. 1991 Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 34:416-422.
5. 5. Moller DE, Bjorbeak C, Vidal-Puig A. 1996 Candidate genes for insulin resistance. Diabetes Care. 19:396-400.
6. 6. Hotamisligil GS, Spiegelman BM. 1996 TNF-α, and the insulin resistance of obesity. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus. Piladelphia: Lippencott-Raven; 554-560.
7. 7. Stephens JM, Lee J, Pilch PF. 1997 Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin-receptor-mediated transduction. J Biol Chem. 272:971-976.
8. 8. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. 1994 Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor α. J Clin Invest. 94:1543-1549.
9. 9. Hotamisligil GS, Murray D, Choy LN, Spiegelman BM. 1994 Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA. 91:4854-4858.
10. 10. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM. 1996 Tumor necrosis factor (TNF)-α inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem. 271:13018-13022.
11. 11. Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A. 1995 Tumor necrosis factor α-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem. 270:23780-23784.
12. 12. Kanety H, Hemi R, Papa MZ, Karasik A. 1996 Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1. J Biol Chem. 271:9895-9897.
13. 13. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. 1995 Increased adipose tissue expression of tumor necrosis factor alpha in human obesity and insulin resistance. J Clin Invest. 95:2409-2415.
14. 14. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. 1995 The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 95:2111-2199.
15. 15. Hotamisligil GS, Shargill NS, Spiegelman BM. 1993 Adipose expression of tumor necrosis factor-a: direct role in obesity linked insulin resistance. Science. 259:87-91.
16. 16. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. 1996 Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 45:881-885.
17. 17. Ventre J, Doebber T, Wu M, et al. 1997 Targeted disruption of the tumor necrosis factor-a gene. Metabolic consequences in obese and non-obese mice. Diabetes. 46:1526-1531.
18. 18. Young TK. 1988 Health care and cultural change: the Indian experience in the central subarctic. Toronto: University of Toronto Press; pp 16-31.
19. 19. Young TK. 1988 Are subarctic Indians undergoing the epidemiologic transition? Soc Sci Med. 26:659-671.
20. 20. McIntyre L, Shah CP. 1986 Prevalence of hypertension, obesity and smoking in three Indian communities in northwestern Ontario. Can Med Assoc J. 134:349-349.
21. 21. Delisle HF, Ekoe J. 1993 Prevalence of non-insulin-dependant diabetes mellitus and impaired glucose tolerance in two Algonquin communities in Quebec. Can Med Assoc J. 148:41-47.
22. 22. Fox C, Harris SB, Whalen-Brough E. 1994 Diabetes among Native Canadians in northwestern Ontario: 10 years later. Chronic Dis Can. 15:92-96.
23. 23. Hanley AJG, Harris SB, Barnie A, et al. 1995 The Sandy Lake Health, and Diabetes Project: design, methods and lessons learned. Chronic Dis Can. 16:149-156.
24. 24. Gittelsohn J, Harris SB, Burris K, et al. 1996 Use of ethnographic methods for applied research on diabetes among Ojibway-Cree Indians in Northern Ontario. Health Educ Q. 23:365-382.
25. 25. Harris SB, Gittelsohn J, Hanley AJG, et al. 1997 The prevalence of NIDDM and associated risk factors in aboriginal Canadians. Diabetes Care. 20:185-187.
26. 26. WHO. 1985 Diabetes mellitus: report of a WHO study group. Geneva: WHO; WHO Technical Rep Ser 727.
27. 27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations. Diabetologia. 28:412-419.
28. 28. Lipid Research Clinics Program. 1984 Manual of laboratory operations. Bethesda: U.S. Government Printing Office; 1-81; DHEW Publication (NIH) 756282.
29. 29. Dawson PJ. 1991 Effect of formulation and freeze-drying on the long-term stability of rDNA-derived cytokines. Dev Biol Standard. 74:273-284.
30. 30. Thavasu PW, Longhurst S, Joel SP, Slevin ML, Balkwill FR. 1992 Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J Immunol Methods 153:115-124.
31. 31. Hanley AJG, Harris SB, Barnie A, Smith J, Logan A, Zinman B. 1994 Usefulness of bioelectrical impedance analysis in a population-based study of diabetes among Native Canadians. Int J Obesity. 18(Suppl 2):O383.
32. 32. Sakamoto Y, Miura J, Yamaguchi Y, Ohno M, Ike Y. 1994 Usefulness of bioelectrical impedance analysis for measurement of body fat. Int J Obesity. 18(Suppl 2):P501.
33. 33. Nunez C, Gallagher D, Visser M, Pi-Sunyer FX, Wang Z, Heymsfield SB. 1997 Bioimpedance analysis: evaluation of a leg-to-leg system based on pressure contact foot-pad electrodes. Med Sci Sports Exerc. 29:524-531.
34. 34. Tsui EYL, Gao XJ, Zinman B. 1998 Bioelectrical impedance analysis (BIA) using bipolar foot electrodes in the assessment of body composition in type 2 diabetes mellitus. Diabetic Med. 15:125-128.
35. 35. SAS Institute. 1990 SAS/STAT user's guide, version 6, 4th ed. Cary: SAS Institute.
36. 36. Weisberg S. 1980 Applied linear regression. New York: Wiley and Sons.
37. 37. Hotamisligil GS, Spiegelman BM. 1994 TNF-α: a key component of obesity-diabetes link. Diabetes. 43:1271-1278.
38. 38. Bemelmans MHA, Van Tis LJH, Buurman WA. 1996 Tumor necrosis factor: function, release and clearance. Crit Rev Immunol. 16:1-11.
39. 39. Mohamed-Ali V, Goodrick S, Rawesh A, et al. 1997 Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab. 82:4196-4200.
40. 40. Warzocha K, Bienvenu J, Coiffier B, Salles G. 1995 Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system. Eur Cytokine Netw. 6:83-96.
41. 41. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. 1995 Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis. Eur J Haematol. 54:1-8.
42. 42. Samsonov MY, Tilz GP, Egorova O, et al. 1995 Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 4:29-32.
43. 43. Schroder J, Stuber F, Galatti H, Schade FU, Kremer B. 1995 Pattern of soluble TNF receptors T and II in sepsis. Infection. 23:143-148.
44. 44. Gattorno M, Picco P, Buoncompagni A, et al. 1996 Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann Rheum Dis. 55:243-247.
45. 45. Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM. 1997 Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes. 46:451-455.
46. 46. Mantzoros C, Moschos S, Avramopoulos I, et al. 1997 Leptin concentrations in relation to body mass index and the tumor necrosis factor-α system in humans. J Clin Endocrinol Metab. 82:3408-3413.
47. 47. Pfeiffer A, Janott J, Mohlig M, et al. 1997 Circulating tumor necrosis factor-α is elevated in male but not in female patients with type II diabetes mellitus. Horm Metab Res. 29:111-114.
48. 48. Kellerer M, Rett K, Renn W, Groop L, Haring HU. 1996 Circulating TNF-α, and leptin levels in offspring of NIDDM patients do not correlate to individual insulin sensitivity. Horm Metab Res. 28:737-743.
49. 49. Hamann A, Mantzoros C, Vidal-Puig A, Flier JS. 1995 Genetic variability in the TNF-α promoter is not associated with type II diabetes mellitus (NIDDM). Biochem Biophys Res Commun. 211:833-839.
50. 50. Norman RA, Bogardus C, Ravussin E. 1995 Linkage between obesity and a marker near the tumor necrosis factor-α locus in Pima Indians. J Clin Invest. 96:158-162.
51. 51. Fernandez-Real JM, Gutierrez C, Ricart W, et al. 1997 The TNF-α gene Nco 1 polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels. Diabetes. 46:1468-1472.
52. 52. Liu Y, Liu T, McCarron RM, et al. 1996 Evidence for activation of endothelium and monocytes in hypertensive rats. Am J Physiol. 270:H2125-H21231.
53. 53. Chou TC, Yen MH, Li CY, Ding YA. 1998 Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension. 31:643-648.
54. 54. Nyui N, Tamura K, Yamaguchi S, et al. 1997 Tissue angiotensinogen gene expression induced by lipopolysaccharide in hypertensive rats. Hypertension. 30:859-867.
55. 55. Brasier AR, Li J, Wimbish KA. 1996 Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension. 27:1009-1017.
56. 56. Ferreri NR, Zhao Y, Takizawa H, McGiff JC. 1997 Tumor necrosis factor-α-angiotensin interactions and regulation of blood pressure. J Hypertension. 15:1481-1484.